Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | Active, not recruiting | Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | Drug, Other, Other, Other - anastrozole, questionnaire administration, laboratory biomarker analysis, pharmacogenomic studies | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - N/A | N/A | Interventional | E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with AIs due to the development of musculoskeletal symptoms (MSS). Women with stage 1-111 breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join. | |
|
Clinicaltrials.gov | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | Active, not recruiting | Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma | Drug, Drug, Other - temozolomide, capecitabine, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors. | ||
|
Clinicaltrials.gov | Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia | Unknown status | Leukemia | Genetic, Genetic, Genetic, Genetic, Genetic, Genetic, Genetic, Other - DNA analysis, fluorescence in situ hybridization, gene expression analysis, microarray analysis, mutation analysis, polymorphism analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 16 Years - 39 Years | Observational | RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This laboratory study is looking into genes in samples from younger patients with acute lymphoblastic leukemia (ALL). | |||
|
Clinicaltrials.gov | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer | Completed | Adenocarcinoma of the Colon, Stage III Colon Cancer | Drug, Drug, Drug, Other - leucovorin calcium, fluorouracil, irinotecan hydrochloride, laboratory biomarker analysis | National Cancer Institute (NCI), Southwest Oncology Group, North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, NIH, Other, Other, Other, Other | 18 Years - N/A | Phase 3 | Interventional | Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon cancer. Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without irinotecan in treating patients who have undergone surgery for stage III colon cancer. | ||
|
Clinicaltrials.gov | Diagnostic Study of Patients With Stage I Testicular Cancer | Completed | Testicular Germ Cell Tumor | Other, Other, Procedure - immunohistochemistry staining method, laboratory biomarker analysis, radionuclide imaging | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | Male | 15 Years - 120 Years | N/A | Interventional | RATIONALE: Diagnostic procedures may improve a doctor's ability to predict the recurrence of testicular cancer. PURPOSE: Diagnostic trial to detect the risk of recurrent disease in patients who have stage I testicular cancer and who have undergone orchiectomy within the previous 12 weeks. | |
|
Clinicaltrials.gov | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13, q22), Adult Acute Myeloid Leukemia With t(16, 16)(p13, q22), Adult Acute Myeloid Leukemia With t(8, 21)(q22, q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | Drug, Drug, Other, Drug, Drug, Other, Procedure, Other - clofarabine, daunorubicin hydrochloride, clinical observation, cytarabine, decitabine, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 60 Years - N/A | Phase 3 | Interventional | This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia. | ||
|
Clinicaltrials.gov | Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy | Completed | Breast Cancer, Estrogen Receptor, Her-2, Pgr | Genetic, Genetic, Other, Other - microarray analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict whether cancer will come back after treatment. PURPOSE: This laboratory study is identifying genes that may help predict recurrence in women with breast cancer treated with chemotherapy. | ||
|
Clinicaltrials.gov | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors | Withdrawn | Cancer | Drug, Procedure, Procedure, Procedure, Procedure - paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis, pharmacological study, polymerase chain reaction | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | N/A | Interventional | RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with advanced or refractory solid tumors. | ||
|
Clinicaltrials.gov | Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim | Completed | Melanoma (Skin) | Genetic, Genetic, Genetic, Other, Other, Other, Other - RNA analysis, in situ hybridization, polymerase chain reaction, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of tissue and blood in the laboratory from patients treated with ipilimumab with or without sargramostim may help doctors learn more about the effects of ipilimumab and sargramostim on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research trial studies tissue and blood biomarkers in patients with stage III melanoma or stage IV melanoma treated with ipilimumab with or without sargramostim. | |||
|
Clinicaltrials.gov | DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402 | Completed | Lymphoma | Biological, Genetic, Genetic, Genetic, Other - rituximab, DNA analysis, gene expression analysis, polymerase chain reaction, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying DNA isolated from blood samples to see how well it influences response to rituximab in patients with follicular lymphoma treated on clinical trial ECOG-E4402. | |||
|
Clinicaltrials.gov | Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy | Completed | Leukemia | Genetic, Genetic, Genetic, Other, Other - DNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of DNA in the laboratory from patients who received fludarabine-based treatment may help doctors learn more about the effects of fludarabine on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying DNA samples from patients with chronic lymphocytic leukemia previously treated with fludarabine-based therapy. | |||
|
Clinicaltrials.gov | Study of Bone Marrow Samples From Patients With Acute Leukemia | Completed | Leukemia | Genetic, Genetic, Genetic, Genetic, Other, Other - gene expression analysis, mutation analysis, polymorphism analysis, protein analysis, flow cytometry, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying the genes expressed in samples of bone marrow from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at bone marrow samples from patients with acute leukemia. | |||
|
Clinicaltrials.gov | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer | Drug, Other, Drug, Drug, Drug, Other, Other - c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group, Other, NIH, Other | 18 Years - N/A | Phase 1/Phase 2 | Interventional | This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating patients with stomach or esophageal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. C-Met inhibitor AMG 337 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving c-Met inhibitor AMG 337 with oxaliplatin, leucovorin calcium, and fluorouracil may kill more tumor cells. | ||
|
Clinicaltrials.gov | Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia | Completed | Leukemia | Genetic, Genetic, Genetic, Other - RNA analysis, cytogenetic analysis, microarray analysis, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 15 Years - 65 Years | Observational | RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial. | |||
|
Clinicaltrials.gov | Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia | Completed | Leukemia | Genetic, Genetic, Other, Other, Other - mutation analysis, protein analysis, laboratory biomarker analysis, liquid chromatography, mass spectrometry | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 17 Years - 60 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia. | |||
|
Clinicaltrials.gov | Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab | Completed | Lymphoma | Genetic, Genetic, Genetic, Genetic, Other, Other - gene expression analysis, microarray analysis, polymerase chain reaction, polymorphism analysis, immunohistochemistry staining method, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying the effects of rituximab in blood and tumor tissue samples from patients with cancer in the laboratory may help doctors learn more about the effects of rituximab on cancer cells. It may also help doctors identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with follicular lymphoma treated with rituximab. | |||
|
Clinicaltrials.gov | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | Active, not recruiting | Breast Cancer | Drug, Other - tamoxifen citrate, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells. PURPOSE: This phase II trial is studying how well tamoxifen citrate works in patients with metastatic or recurrent breast cancer. | ||
|
Clinicaltrials.gov | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | Active, not recruiting | Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx | Procedure, Radiation, Drug, Drug, Radiation, Other, Other - therapeutic conventional surgery, intensity-modulated radiation therapy, cisplatin, carboplatin, intensity-modulated radiation therapy, laboratory biomarker analysis, quality-of-life assessment | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery. | ||
|
Clinicaltrials.gov | Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial | Completed | Head and Neck Cancer | Genetic, Genetic, Genetic, Other - mutation analysis, polymerase chain reaction, polymorphism analysis, laboratory biomarker analysis | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in samples from patients with recurrent or metastatic head and neck cancer treated on ECOG-E1302 trial. | |||
|
Clinicaltrials.gov | Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide | Completed | Multiple Myeloma and Plasma Cell Neoplasm | Genetic, Genetic, Other, Other, Other - gene expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, laboratory biomarker analysis, platelet aggregation test | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Other, NIH | N/A - 120 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood samples from patients with multiple myeloma who were treated with thalidomide or lenalidomide. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
